RNS Number : 3566S
N4 Pharma PLC
09 March 2023

9 March 2023

N4 Pharma plc

("N4 Pharma" or the "Company")

Posting of Annual Report & Notice of AGM

N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, announces that its Annual Report and Accounts for the year ended 31 December 2022 and Notice of its Annual General Meeting ("AGM") has been posted to shareholders.

The AGM will be held at 11.00 a.m. on 3 April 2023 at Shakespeare Martineau LLP, 6th Floor 60 Gracechurch Street, London, EC3V 0HR.

The Group's Annual Report and Accounts and the Notice of AGM will be made available on the Company's website: https://www.n4pharma.com/

Enquiries:

N4 Pharma plc
Nigel Theobald, CEO — Via IFC Advisory
Luke Cairns, Executive Director

SP Angel Corporate Finance LLP — Tel: +44(0)20 3470 0470
Nominated Adviser and Joint Broker
Matthew Johnson/Kasia Brzozowska (Corporate Finance)
Vadim Alexandre/Abigail Wayne/Rob Rees (Corporate Broking)

Turner Pope Investments (TPI) Limited — Tel: +44(0)20 3657 0050
Joint Broker
Andy Thacker
James Pope

IFC Advisory Ltd — Tel: +44(0)20 3934 6630
Financial PR
Graham Herring
Zach Cohen

About N4 Pharma

N4 Pharma is a specialist pharmaceutical company developing a novel delivery system for cancer and vaccine treatments using its unique silica nanoparticle delivery system called Nuvec®.

N4 Pharma's business model is to partner with companies developing novel antigens for cancer and vaccine treatments to use Nuvec® as the delivery vehicle to get their antigen into cells to express the protein needed for the required immunity. As these products progress through preclinical and clinical programs, N4 Pharma will seek to receive up front payments, milestone payments and ultimately royalty payments once products reach the market.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NOASSEFWAEDSELD